|
|
||||||||
J Thorac Cardiovasc Surg 2008;135:1322-1326
© 2008 The American Association for Thoracic Surgery
Evolving Technology |
a Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria
b Department of Cardiology, University Hospital Rostock, Rostock, Germany
c Department of Radiology, Centre Hospitalier Universitaire, Hopital de Rangueil, Toulouse, France
d Radiologie Vasculaire, Hopital Cardiologique CHRU de Lille, Lille, France
e Centre Hospitalier Universitaire, Hopital Sainte Marguerite, Marseille, France
f Department of Cardiothoracic Surgery, St Antonius Hospital, Nieuwagein, The Netherlands
g Centre Hospitalier Universitaire, Hopital de la Timone, Marseille, France
h Department of Internal Medicine, University of Vienna, Vienna, Austria
i Cardiovascular Radiology, University Hospital S. Orsola, Bologna, Italy
Received for publication May 28, 2007; revisions received September 2, 2007; accepted for publication September 12, 2007. * Address for reprints: Rossella Fattori, MD, Department of Radiology-Cardiovascular Unit, University Hospital S. Orsola, Via Masseranti 9, 40128 Bologna, Italy. (Email: rosella.fattori{at}unibo.it).
| Abstract |
|---|
|
|
|---|
Methods: We analyzed data from 422 of 457 consecutive patients who underwent endovascular thoracic repair with the Medtronic Talent thoracic stent-graft (Medtronic/AVE, Santa Rosa, Calif). Of these, 16 patients (3.8%) required late conversion to open surgery during a median follow-up interval of 17 months (range 7–33 months). Six of these patients had undergone previous aortic surgery, 3 patients had previous cardiac surgery, and 5 patients had Marfan syndrome. In patients with late conversion, indications for primary stent-graft placement were dissection in 10 patients, degenerative aneurysm in 5 patients, and penetrating ulcer in 1 patient.
Results: By multivariable Cox analysis, Marfan syndrome (adjusted hazard ratio 9.97, P = .008), type I endoleak (adjusted hazard ratio 3.99, P = .012), the use of more than 1 stent-graft (adjusted hazard ratio 3.89, P = .018), and procedural complications (adjusted hazard ratio 17.50, P = .003) were independent predictors of late conversion.
Conclusion: Endovascular treatment for thoracic aortic disease with the Talent stent-graft is associated with a relatively low rate of late conversion to conventional surgery. Better results may be achieved by excluding patients with Marfan syndrome for such a procedure and early aggressive treatment of early type I endoleaks.
| Introduction |
|---|
|
|
|---|
Since the first endovascular stent-graft (ESG) experience in an abdominal aortic aneurysm,7
various groups have started to investigate the feasibility of thoracic aortic aneurysmal repair with ESGs.8,9
During the last decade, endovascular techniques have revolutionized the management of descending thoracic aortic disease, with the benefit of exclusion of the pathologically altered aorta without direct surgical exposure. Although an endovascular technique was initially reserved for patients not suitable for conventional surgery, clinical success led to rapid expansion of indications.10,11
Nevertheless, both the potential risk of device failure and the concern about long-term durability remain unresolved issues with this emerging treatment modality. The Talent Thoracic Registry was designed to collect outcome data from patients who underwent endoluminal treatment with the Medtronic Talent thoracic stent-graft (Medtronic/AVE, Santa Rosa, Calif) in 7 European referral centers, and short-term results were reported.12
For this article, data collection and analysis were particularly focused on predictors of late conversion to open surgery after thoracic ESG placement.
| Materials and Methods |
|---|
|
|
|---|
Device Description
The Talent thoracic stent-graft is composed of Dacron graft fabric supported by self-expanding nitinol springs. The springs are sewn to the graft material with polyester sutures. The graft material is a sheet of monofilament polyester with a seam joining the edges to create a cylindric tube. The connecting bar provides columnar strength to the device and facilitates deployment. All nitinol components are surface treated to enhance long-term fatigue performance. The Talent stent-graft system has many modular sections that can be used to treat a wide variety of thoracic lesions. The stent-graft has 3 proximal and distal configurations. The proximal configurations are FreeFlo, Bare Spring (22 mm only), and Open Web, all of which all have a flared geometry. The FreeFlo design (different from the Bare Spring configuration) has a bare spring and a mini-support spring, which improves sealing for sizes 24 to 46 mm. The distal configurations are Bare Spring, Closed Web, and Open Web. The Open Web configuration was designed for use as distal extensions for the Talent stent-graft system.
Indication for Operation
The indication for conventional surgery after primary stent-graft placement in these 16 patients was a progressive expansion of the aneurysm in 14 cases and impending rupture in 2 patients.
Operative Technique
The operative technique was selected according to the localization of the secondary pathology from either endoleaks or other causes in the distal arch or descending aorta. Patients underwent operation by arch replacement via a median sternotomy or distal arch and descending thoracic aorta replacement via a left thoracotomy. Either deep hypothermic circulatory arrest or left heart bypass technique was used.5,13
Patients who required deep hypothermic circulatory arrest were cooled to 18°C, and circulatory arrest was initiated. One patient who experienced an acute retrograde type A dissection 6 months after ESG placement for primary acute type B dissection underwent ascending aorta and a frozen elephant trunk repair through a median sternotomy.14
In this patients, antegrade cerebral perfusion was used as an additional brain protection technique. In all 16 patients, the aneurysmal sac was longitudinally opened and any stent-grafts were harvested. Intercostal arteries were not reimplanted in any of the 16 patients. The aneurysm was replaced by a Dacron prosthesis.
Statistical Analysis
Continuous data are reported as the mean ± standard deviation or median and total range. Univariate comparisons were done by chi-square tests or Mann–Whitney U tests, as appropriate. Estimates of times to events and the accompanying curves were generated by the method of Kaplan–Meier. Multivariable Cox proportional hazards analysis was applied to determine independent predictors of late conversion adjusting for potential confounders. Baseline variables that were imbalances between patients with and without late conversion by a P value less than .05 were entered into the models. The results of the Cox models are reported as hazard ratios and 95% confidence intervals. We tested for interactions between baseline variables by multiplicative interaction terms and log likelihood chi-square tests. We assessed the overall model fit using Cox–Snell residuals. Furthermore, we tested the proportional hazard assumption for all covariates using Schoenfeld residuals (overall test) and the scaled Schoenfeld residuals (variable-by-variable testing). According to the tests, the proportional hazards assumption was not violated. Statistical analysis was carried out with SPSS software package version 13.0 (SPSS, Inc, Chicago, Ill).
| Results |
|---|
|
|
|---|
|
Procedural characteristics of the initial stent-graft implantation are listed in
Table 2. Patients who underwent late conversion had a larger maximal aortic aneurysmal diameter at the time of the primary stent-graft placement (77 mm vs 54 mm; P = .01), and several patients in this group needed more than 3 stent-grafts to cover the aneurysmal sac (P = .01). Furthermore, the presence of early endoleak was significantly higher in the late conversion group (43.8% vs 15.8%; P = .003).
|
By multivariable Cox analysis, Marfan syndrome (adjusted hazard ratio 9.97, P = .008), type I endoleak (adjusted hazard ratio 3.99, P = .012), the use of more than 1 stent-graft (adjusted hazard ratio 3.89, P = .018), and procedural complications (adjusted hazard ratio 17.50, P = .003) were independent predictors of late conversion. The variables age, gender, previous cardiac surgery, maximal aortic diameter, acute operation, and aortic dissection showed no significant association with late conversion (
Table 3).
|
| Discussion |
|---|
|
|
|---|
Transluminal placement of ESGs has been used to treat abdominal aortic aneurysms and descending thoracic aortic pathologies.8
Stent-graft repair of the descending thoracic aorta seems to offer a feasible and safe alternative compared with conventional repair.16-18
Although long-term follow-up is limited, clinical results have been promising.12
Stent-graft placement may be of particular benefit, especially in high-risk patients, because this new procedure is easier and less invasive than the conventional surgical approach.19
We and others have shown that this method for treating thoracic aortic disease is associated with low early morbidity and mortality rates for patients at high risk and treated on an emergency base, as well as a good long-term outcome.12
In addition to the low incidence of late conversions, the morbidity and mortality rate associated with this late conversion to conventional surgery was much lower than other investigators have found in abdominal aneurysms.20,21
Only 1 of the 16 patients died after the procedure. The other 15 patients experienced no major postoperative complication and had an uneventful recovery.
By multivariable Cox analysis, Marfan syndrome, procedural complications, type I endoleak, and the use of more than 1 stent-graft were significant predictors of late conversion. Procedural complications occurred in 2 patients: The dissection extended into the proximal aorta after stent-graft placement in 1 patient, and the stent-graft dislocated on deployment in 1 patient. Both patients underwent operation conventionally 5 and 6 weeks after the primary procedure. The occurrence of late endoleak formation requiring elective surgical reintervention after stent-graft placement was acceptably low in this study (1.9%). It was primarily observed after ESG for aortic type B dissection (62.5%). Late type I endoleaks resulting from chronic enlargement of the proximal or distal landing zone developed in 3 patients. In addition to the progression of the underlying atherosclerotic disease, short proximal or distal landing zones were causative for treatment failure. One of our patients with a type I endoleak exhibited a proximal landing zone of less than 20 mm in length, although a subclavian to carotid artery transposition was performed before the ESG. The remainder with type Ib endoleaks showed a critical distal landing zone at the time of implantation, which was characterized by partial thrombus formation at the aortic wall and a critical diameter of 38 mm.
The risk of retrograde aortic dissection after ESG has been reported.14
We observed this fatal complication in 1 patient. Injury of the intima by the bare springs of the Talent stent-graft device is suspected to be the cause of this complication. Although this stent-graft–related complication is rare and occurred in only 1 patient in this large series, the development of specially designed stent-grafts for aortic dissection is warranted. The expansion of stent-grafts in the friable tissue of an acute dissected aorta is different than the deployment of ESG in chronic atherosclerotic aneurysms. In atherosclerotic aneurysms, the anchorage of the ESG is dependent on a relatively short proximal and distal landing zone, which necessitates high radial forces generated by the stent. In contrast, ESGs for the treatment of acute dissections have to be designed differently with respect to radial force and flexibility. Because the entire length of the ESG is in contact with the aortic wall, less radial force is sufficient to ensure proper fixation of the ESG. Moreover, increased flexibility of the device will reduce the risk for subsequent injury of adjacent aortic tissue.
Most important, the incidence of late conversion after stent-graft placement was significantly high in patients with Marfan syndrome. Five of the 16 patients (31.3%) who required late open surgery had this connective tissue disease. In light of this remarkable finding, patients with Marfan syndrome should not be treated with endovascular stent-grafts because of their thin, weak, and friable aortic wall that will predispose them to further developing false aneurysm or endoleaks.
Although impressive results and amazing developments have been achieved since the first introduction of ESG in 1991, this technology is still in its infancy. The potential risk of device failure and the concern about long-term durability constitute the major unresolved issues in this emerging treatment modality. Emphasis should be placed on appropriate case selection and the stringency of lifelong surveillance after endovascular therapy, which will further elucidate the indications and limitations of this innovative therapy.
| Conclusions |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. Canaud, P. Alric, T. Gandet, B. Albat, C. Marty-Ane, and J.-P. Berthet Surgical conversion after thoracic endovascular aortic repair J. Thorac. Cardiovasc. Surg., November 1, 2011; 142(5): 1027 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Garbade, M. Jenniches, M. A. Borger, M. J. Barten, D. Scheinert, M. Gutberlet, T. Walther, and F.-W. Mohr Outcome of patients suffering from acute type B aortic dissection: a retrospective single-centre analysis of 135 consecutive patients Eur J Cardiothorac Surg, September 1, 2010; 38(3): 285 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cheng, J. Martin, H. Shennib, J. Dunning, C. Muneretto, S. Schueler, L. Von Segesser, P. Sergeant, and M. Turina Endovascular Aortic Repair Versus Open Surgical Repair for Descending Thoracic Aortic Disease: A Systematic Review and Meta-Analysis of Comparative Studies J. Am. Coll. Cardiol., March 9, 2010; 55(10): 986 - 1001. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |